Completed
Serotonin system loss in AD early but not universal, interacts with ATN
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Treatment Development for Neuropsychiatric Disturbances in Dementia: Past, Present, Future - Grand Rounds
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Learning objectives
- 3 Facing reality: balancing "cure" with "care"
- 4 Auguste D: hospitalized for delusions and change in personality, not cognitive impairment
- 5 NPS are UNIVERSAL (97%) & fluctuate Cache County Dementia Progression Study
- 6 Eco-psychosocial interventions behavioral, environmental, caregiver focused
- 7 Medication treatment development for NPS The past: BEFORE 2011
- 8 Medication Rxs disappointing when using existing DSM/ICD phenotypes
- 9 Antipsychotics: small benefit Antipsychotics carry "BLACK BOX" warning
- 10 Challenges of DSM-IV phenotypes
- 11 Overlap of symptoms Cache County Dementia Progression Study
- 12 Hypotheses based on etiology
- 13 The future: 2023 and beyond Novel medications for agitation
- 14 Serotonin system loss in AD early but not universal, interacts with ATN
- 15 Response limited to a subgroup HETEROGENEITY
- 16 Response depends on agitation phenotype Affective vs. Dysexecutive
- 17 Breaking down the heterogeneity of NPS The future: 2023 and beyond
